Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
DIAXONHIT - Heart transplant monitoring AlloMap®, the new molecular test to monitor heart transplant patients PARIS and STRASBOURG, France, May 25, 2016 (GLOBE NEWSWIRE) -- DIAXONHIT...
-
PARIS, Jan. 27, 2016 (GLOBE NEWSWIRE) -- DIAXONHIT (Alternext : ALEHT, FR0004054427), a French leader in specialty in vitro diagnostics for transplantation, infectious diseases and cancer, announces...
-
DIAXONHIT - AlloMap® Heart Transplant Surveillance Solution Clinical utility and performance of the AlloMap® heart transplant test confirmed in European study CARGO II clinical...
-
DIAXONHIT - Prosthetic joint infections test DIAXONHIT announces the CE marking of the BJI InoPlex® test and its commercial launch The first and only non-invasive serological test...
-
DIAXONHIT - Heart transplant test DIAXONHIT announces that Strasbourg University Hospital will become its European Central Laboratory for processing the CareDx® AlloMap® heart...
-
The first non-invasive, quick and objective test for identification of antibacterial antibodies from a simple blood sample A test targeting different families of bacteria, particularly...
-
Final performance and CE marking expected before the end of 2014 Commercial launch early 2015, strengthening Diaxonhit's diagnostic product offering in infectious diseases PARIS,...
-
US - Europe AlloMap Symposium Four new clinical abstracts highlighting the clinical utility of AlloMap Paris, May 5, 2014 (GLOBE NEWSWIRE) -- Diaxonhit (Alternext : ALEHT) sponsored and...
-
2013 consolidated income increases to €30.5 million 11% growth of in vitro diagnostic product sales PARIS, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Diaxonhit, the leading French provider of...